How to Sequence Therapies in Mycosis Fungoides.
Caitlin M BrumfielMeera H PatelPranav PuriJake Besch-StokesScott LesterWilliam G RuleNandita KheraJason C SluzevichDavid J DiCaudoNneka ComfereN Nora BennaniAllison C RosenthalMark R PittelkowAaron R MangoldPublished in: Current treatment options in oncology (2021)
Choice of therapy in mycosis fungoides is based on both patient- and lymphoma-specific factors, such as disease characteristics, comorbidities, symptoms and effect on quality of life, potential associated toxicities of therapy, response and tolerance to prior lines of therapy, and convenience and practicality. Generally, we sequence therapies from least toxic, targeted, nonimmunosuppressive to more toxic, immunosuppressive and from single agent to multiple agents, as necessary. If more toxic, immunosuppressive agents are required to alleviate disease burden or symptoms, we generally use them just long enough to control the disease, then transition to a maintenance regimen with less toxic, less immunosuppressive agents.